Maternal-Neonatal Raltegravir Population Pharmacokinetics Modeling: Implications for Initial Neonatal Dosing

• Үндсэн зохиолчид: Jos Lommerse (Зохиогч), Diana Clarke (Зохиогч), Thomas Kerbusch (Зохиогч), Henri Merdjan (Зохиогч), Han Witjes (Зохиогч), Hedy Teppler (Зохиогч), Mark Mirochnick (Зохиогч), Edward P. Acosta (Зохиогч), Larissa Wenning (Зохиогч), Sharon Nachman (Зохиогч), Anne Chain (Зохиогч)
• Формат: Ном
• Хэвлэсэн: Wiley, 2019-09-01T00:00:00Z.
• Нөхцлүүд: article
• Онлайн хандалт: Connect to this object online.

Raltegravir readily crosses the placenta to the fetus with maternal use during pregnancy. After birth, neonatal raltegravir elimination is highly variable and often extremely prolonged, with some neonates demonstrating rising profiles after birth despite removal from the source of extrinsic raltegra...